References: Hair growth and hair loss
Contracept Fertil Sex (Paris). 1982 Oct;10(10):653-7.
[Clinical use of ethinyl estradiol in combination with cyproterone acetate. Study based on 50 cases (author's transl)]
[Article in French]
Henrion R, Laveissiere MN.
PIP: A combination of 50 mcg of ethinyl estradiol (EE) and 2 mg cyproterone acetate was prescribed for 50 women seeking oral contraceptives who showed signs of hyperandrogenism. The women averaged 25 years of age and the treatments lasted an average of 12 months. Very satisfactory results were seen in 32 of the 43 cases of acne within 4 cycles, and in 6 other cases the results were slower. Results depended on the severity of the acne. Satisfactory results were obtained in 22 of 27 cases of seborrhea, usually within the 1st 4 cycles. Results with hirsutism were satisfactory in 9 of 11 cases but the improvement was slow and often incomplete due to the weak dosage of cyproterone acetate. In all 3 cases of alopecia the results were satisfactory but the improvement came slowly. Most patients reported more regular periods, 8 reported spotting, 11 reported enlargement of breasts with heaviness and sensitivity, none reported effects on the libido, 8 reported nausea which disappeared rapidly, 10 reported headaches, 7 reported heaviness of legs, 5 reported gaining 2 kilos or more but 6 reported losing, and 8 reported mood problems. The only biological change noted in the sample was elevation in triglycerides in 5 women and transitory fluctuations in 7 others. The combination of EE and cyproterone acetate appears to be an excellent choice for young women with signs of hyperandrogenism.
online pharmacy ref. source: www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=12338447&dopt=Abstract
Fertil Contracept Sex. 1988 Apr;16(4):299-304.
[Dermatological complications caused by oral contraceptives]
[Article in French]
Deharo C, Berbis P, Privat Y.
PIP: The incidence of cutaneous effects of oral contraceptives (OCs) is estimated at 2.7-5%. Secondary effects directly attributable to the hormonal action of OCs include melasma, acne and hyperseborrhea, alopecia, and cutaneous lesions of vascular origin. Melasma or chloasma accounts for about 2/3 of all cutaneous side effects of OCs. It appears from 1 month-3 years after the start of OC use, its frequency increasing with dose and duration of use. Pigmentation appears to accentuate the symptoms in brunettes rather than predisposing them to melasma. Exposure to the sun plays a certain role, but use of a low dose OC and effective sun protection are not enough to reverse the pigmentation. These melasmas regress more slowly than after pregnancy and many remain definitive. The influence of OCs on acne is variable, with some OCs provoking sebaceous hypersecretion and some improving acne enough to be used for treatment. For the therapeutic effect to be observed, the estrogen dose must be sufficient to offset the androgenic effect of the progestin. Combined pills containing the strong antiandrogen cyproterone acetate should control acne if other, less androgenic progestins fail. Alopecia is a very rare effect of OCs and its appearance may even reflect simple coincidence. Vascular complications of combined OCs are dependent on estrogens and may include such manifestations as telangiectasias, angiomas, and livedo reticularis. Some secondary cutaneous effects are probably not due to a hormonal influence. They are less well known than the direct hormonal effects, and publications concerning the often detail isolated observations that are difficult to interpret. Reactions of hypersensitivity or allergy to combined OCs may include urticaria and eczema. A history of OC use should be sought in all women presenting with erythema nodosum and the OCs should be discontinued. Pruritus and jaundice may be observed in 1 OC user in 100,000. They indicate a cholestatic hepatitis for which estrogens are responsible. Most patients developing the condition have already had pruritus or jaundice during pregnancy; such a history contraindicates OC use. Several dermatological and systemic disorders are aggravated by OC use. Hereditary angioedema, herpes gestationis, porphyries, and systemic lupus erythematosus are exacerbated by OC use. The role of OCs in malignant melanomas remains controversial.
online pharmacy ref. source: www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=12342376&dopt=Abstract
yahoo.com
OBJECTIVES/HYPOTHESIS: To evaluate the treatment of facial verrucae with the pulsed dye laser. STUDY DESIGN: A prospective, nonrandomized, nonblinded pilot study evaluating the treatment of facial verrucae with the pulsed dye laser. METHODS: Twelve patients with facial verrucae (four recalcitrant) were identified and followed in the study in the setting of a tertiary referral center. The treatment consisted of the flash-lamp pumped pulsed dye laser (585 mn) with a spot size of 5 mm at fluences between 9.0 and 13 J/cm. Each lesion received one or two pulses with 2 mm of surrounding normal skin included in the treatment. One patient had paring prior to pulse treatment. The patients were examined 3 to 4 weeks after each procedure, and clinical assessment of the lesion was documented. RESULTS: Patient ages ranged from 18 to 47 years. Four patients had refractory lesions, and eight patients had never undergone previous treatment. All 12 patients had full resolution of their facial warts after one to three treatment sessions. No complications such as scarring, alopecia, or recurrence were encountered. Follow-up ranged from 10 to 33 months. CONCLUSIONS: Pulsed dye laser therapy is highly effective and safe therapy for facial verrucae. This method appears to selectively destroy warts without damaging surrounding skin.
online pharmacy ref. source: www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=12352665&dopt=Abstract
Natural Herbal Supplements ||
Hair Million herbal formula for hair loss and hair growth ||
Hair growth research references ||
Online Pharmacy : discount prescription medication ||